Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2023 | How donor age impacts outcomes in patients with AML undergoing alloSCT

Wael Saber • 21 Oct 2023
COSTEM 2023
Acute Myeloid Leukemia Leukemia

In this video, Wael Saber, MD, MS, Froedtert & Medical College of Wisconsin, Milwaukee, WI, explains the benefits of using younger donors when transplanting patients with acute myeloid leukemia (AML), highlighting the drawbacks of using older donors. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Wael Saber

1:05
Using whole genome sequencing to identify novel predictors for SCT in patients with MDS
Wael Saber • 21 Oct 2023
1:40
Unrelated younger donors vs older sibling donors when transplanting patients with MDS & AML
Wael Saber • 21 Oct 2023
1:13
Selecting conditioning regimens for patients with myelofibrosis undergoing alloSCT
Wael Saber • 21 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals